96428-51-2Relevant academic research and scientific papers
3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES
-
, (2017/04/04)
The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
-
, (2014/05/20)
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
-
, (2014/05/20)
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
IMIDAZOPYRIDINE COMPOUNDS
-
Paragraph 0292; 0442, (2014/04/03)
[Problem] An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. [Means for Solution] It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.
Antinuclear Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazopyridines
Kaminski, James J.,Bristol, James A.,Puchalski, Chester,Lovey, Raymond G.,Elliott, Arthur J.,et al.
, p. 876 - 892 (2007/10/02)
A novel class of antinuclear agents, the substituted imidazopyridines, is described.The present compounds are not histamine (H2) receptor antagonists nor are they prostaglandin analoques, yet they exhibit both gastric antisecretory and c
Imidazo[1,2-A]pyridines and use
-
, (2008/06/13)
This invention relates to imidazo[1,2-a]pyridine derivatives which are useful in the treatment of peptic ulcer diseases.
